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ABSTRACT 
STUDY ON THE ROLE OF HIGH  SENSITIVITY C-REACTIVE 
PROTEIN IN ACUTE EXACERBATION OF CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
ABSTRACT 
BACKGROUND 
           Chronic obstructive pulmonary disease remains the second most common 
disorder affecting the lungs,next only to pulmonary tuberculosis in India. 
Patients with COPD will experience a systemic inflammation. Recently hs-CRP 
measuring methods have made it possible to assess this protein even in lower 
levels of inflammation. 
AIMS OF THE STUDY: 
          Our aim is to study the levels of hs-CRP in acute exacerbation of COPD 
patients and to assess the correlation of hs-CRP with the severity of the disease 
and also with respect to other variables such as age, sex, BMI and smoking 
habits. 
MATERIALS AND METHODS: 
Patients with clinically diagnosed and spirometrically confirmed cases of COPD 
with acute exacerbation were included in the study and classified based on 
GOLD staging. This was a cross sectional study, conducted in Thanjavur 
medical college and hospital between October 2011 and November 2012. The 
sample size was 70 patients. Serum hs-CRP levels were measured by 
nephelometry method. Those  patients with  serum hs-CRP levels  >0.3mg/dl 
are considered as high risk individuals. 
RESULTS: 
          The levels of hs-CRP were significantly elevated in acute exacerbation of 
COPD.There exists a positive correlation with severity of the disease, male 
COPD patients, obese individuals and smokers. There was no association of hs–
CRP levels with age and duration of the disease. 
CONCLUSION: 
         Serum hs-CRP levels may be used as a simple auxiliary marker in staging 
determining the severity and prognosis of COPD for early intervention. 
Key words: High sensitivity C-reactive protein; Acute exacerbation of COPD, 
Nephelometry, Spirometry. GOLD staging. 
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INTRODUCTION 
Chronic obstructive pulmonary disease has been defined by the global  
initiative for chronic obstructive lung disease(GOLD)1 as a disease state 
characterised by air flow limitation that is not fully reversible,  usually 
progressive and is associated with an abnormal inflammatory response of 
the lung to inhaled noxious particles or gases. 
Chronic obstructive pulmonary disease includes2,3 
1.EMPHYSEMA-  abnormal permanent enlargement of air spaces distal to 
the terminal bronchioles along with destruction of their walls without any 
fibrosis. 
2.CHRONIC BRONCHITIS: Chronic bronchial mucus hypersecretion 
resulting in chronic expectoration ( coughing out of sputum on most days 
during atleast 3 consecutive months in 2 successive years). 
3.SMALL AIRWAY DISEASE:narrowing of small bronchioles. 
GOLD estimates that Chronic obstructive pulmonary disease is the 6th 
most common cause of death world wide4 and it is predicted that it will be 
the 3rd most common cause of death in future (2020). 
 
 
In India, after pulmonary tuberculosis , Chronic obstructive 
pulmonary disease remains the second most common disorder affecting the 
lung. 
Chronic obstructive pulmonary disease is frequently seen in middle 
aged individuals. It is more commonly seen in males due to increased 
prevalence of smoking in our setup. 
It is equally prevalent both in rural and urban areas. 
Increasing urbanization and emergence of industries leading to air 
pollution and increased smoking among young people may have definite 
impact on the incidence of Chronic obstructive pulmonary disease. 
Some of the predisposing factors in childhood for development of 
Chronic obstructive pulmonary disease in future includes low birth weight , 
malnutrition and recurrent respiratory tract infection. 
In patients with Chronic obstructive pulmonary disease the most 
robust test in assessing the air flow limitation is the spirometry5. 
A low FEV1 (FEV1< 80%) with FEV1/FVC ratio less than 0.7 and 
lessthan 15% reversibility of airflow obstruction post bronchodilator therapy 
is the diagnostic criteria for Chronic obstructive pulmonary disease. 
 
 
With the wide spread use of spirometry,  identification of air flow 
obstruction is considered as a key factor in determining the disability of 
Chronic obstructive pulmonary disease patients. 
Patients with Chronic obstructive pulmonary disease will experience 
a systemic inflammation. 
It is assessed by measuring the inflammatory mediators like C-
reactive protein. 
Recently high sensitivity C-reactive protein (hs-CRP) measuring 
methods have made it possible to assess this protein even in lower levels of 
inflammation. 
 
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
1.To study the levels of high sensitivity C-reactive protein in acute 
exacerbation of COPD patients. 
2.To assess the correlation of high sensitivity C-reactive protein levels with 
various stages of COPD. 
3.To compare the levels of high sensitivity C-reactive protein in obese and 
non-obese individuals. 
4.To evaluate the correlation of hs-CRP in COPD patients with respect to 
other variables such as age,sex and smoking habits. 
 
  
 
 
 
REVIEW OF LITERATURE 
From the time of Laennec., et al throughout the first half of the 20th 
century, mechanical explanations of chronic obstructive pulmonary disease 
dominate. 
As early as in 1905 OPIE et al.,  suggested that serine proteases and 
antiproteases imbalance plays an important role in  pathophysiology of 
emphysema. 
In 1956 Medical council of research first used the terminology  
chronic bronchitis in patients with chronic cough with sputum production. 
In 1959 the causal relation between the smoking and persistent cough 
with expectoration was  explained by Higgins.,et al. 
In 1960 Owen and Campbell et al observed the pathological 
changes in airway due to cigarette smoking. 
In 1973 Boughly et al,. submitted a list of  articles related to 
prognostic factors in COPD and importance of pulmonary function test in 
these patients. 
In 2007 Sanja marevic et al.,67 concluded that levels of high 
sensitivity C-reactive protein were significantly higher in patients with 
 
 
COPD and hence proved that it will be a more sensitive marker than TNF-
alpha, CXCL-8 and big ET 1 in systemic circulation. 
Daiana stolz et al.,68in 2007 analysed the levels of copeptin, C-
reactive protein, procalcitonin in acute exacerbation of COPD patients and 
all are found to be significantly elevated. 
Yannick MTA et al.,69 from Erasmus university in 2008 observed 
the predictive role of high sensitivity C-reactive protein for COPD in 
smokers. 
In 2008-2009 SA Alavi et al.,70from Guilan university, Iran found a 
correlation between the levels of  high sensitivity C-reactive protein based 
on the  GOLD staging of COPD. 
Bridevaux et al.,71 in 2009 in his SAPALDIA cohort study (swiss 
study on air pollution and lung diseases in adults) correlated the elevated 
levels of high sensitivity C-reactive protein in association with fast decline 
of FEV1 and obese patients. 
In 2010 Lisa Tileman et al.,72 from Germany identified the distinct 
aspects of systemic inflammation in bronchial asthma and COPD by 
measuring the levels of high sensitivity C-reactive protein (significantly 
elevated in COPD)and Ig E, blood eosinophils, fractional exhaled nitric 
 
 
oxide levels(elevated in bronchial asthma).  He also suggested that these 
markers have replaced the role of spirometry when not available. 
Jack et al.,73 in 2010 concluded that levels of high sensitivity C-
reactive protein and surfactant protein D levels are higher in acute 
exacerbation of COPD which indicates the infectious state in our body. So it 
can also be used as a guide in the treatment of acute exacerbation of COPD. 
Recent study conducted in Maulana Azad medical college in New 
Delhi correlated the levels of hs-CRP as a marker of functional disability in 
COPD patients.  
  
 
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
It is a preventable and treatable condition characterized by 
progressive air flow limitation that is not fully reversible.It includes a group 
of conditions that occurs due to pathological changes in large and small 
airways as well as lung parenchyma.It is due to abnormal inflammatory 
response in lungs to inhaled noxious particles and gases. 
In clinical practice,the diagnosis of COPD should be thought in 
patients above 35yrs of age,those with chronic progressive symptoms 
(cough,wheeze,breathlessness) and other risk factors such as cigarette 
smoking and occupational or environmental dusts or gases. 
Prevalence in India: 
In males the prevalence rate is 2.12 to 9.4% in North India compared 
to 1.4 - 4.08%  in South  India.5,6 In females the prevalence is less which is 
about 1.3-4% from North India and 22.5-2.7 % in South India7. 
 In general the male female ratio is about 1.6:1.0 
COPD and its comorbidities: 
1.Diabetes 
2.Ischemic Heart Disease 
3.Depression 
 
 
4.Osteoporosis 
5.Weight Loss 
6.Peptic Ulcer Disease 
7.Glaucoma 
Natural history and prognosis:8,9,10 
FEV1 declines at a rate of 20-30m/hour in non-smokers, whereas in 
smokers the decline rate will be more than 50ml/per hour. FEV1 is a strong 
predictor of survival. Only less than 50% of patients whose FEV1 less than 
30% may survive 5 years and above. 
Recent studies showed that the BODE index which includes FEV1, 
dyspnea, body weight, 6 minutes walk test are important in predicting the 
prognosis than FEV1 alone. 
RISK  FACTORS: 
Smoking: 
Most commonly identified correlate with chronic bronchitis is 
cigarette smoking.The mortality rate varies with the dose response curve 
with pack years of smoking.11 
 
 
When compared to nonsmokers, there is a 25% increase in mortality 
in smokers. The mortality in pipe and cigar smokers is lower than the 
cigarette smokers. Filter tip cigarettes are comparably less harmful.  
Incidence of the disease decreases if smoking is stopped early in the 
course of the disease.12,13Cessation of smoking do not normalize the lung 
functions, instead it slows down the deterioration. 
In males the loss of FEV1 in excess of normal decline with aging is 
9ml per year for each pack year of smoking. In females, the rate of decline 
in FEV1 is  6ml14. 
Prolonged smoking impairs the ciliary motility, macrophages 
accumulate in higher quantities in respiratory bronchioles which in turn 
releases proteinases and is responsible for destruction of extracellular matrix 
of lung. These macrophages recruit chemotactic factors which in turn 
attracts other inflammatory cells to lung and causes mucus gland 
hyperplasia. 
Cigarette smoke inhibits anti proteases and releases proteolytic 
enzymes, thereby destroying the alveolar wall17. 
Passive smoking otherwise called as environmental tobacco smoke 
exposure15,16plays an important role in nonsmokers particularly among the 
women. 
 
 
Air pollution: 
Pollutants for air pollution includes exhausts from automobiles, 
industries and factories.18,19,22 
Smoke from solid fuel combustion such as dried dung, wood crop 
residues used in cooking in villages and slum areas also contributes to major 
source of air pollution in developing countries like India20,21. 
Occupation : 
According to American thoracic society the occupational contribution 
to the burden of COPD is around 15%.23,24 
Various studies from all over the world quoted that occupation 
involving exposure to dust, gases, fumes as a major contributing factor to 
COPD. 
Chronic bronchitis is more prevalent among workers exposed to 
organic or inorganic dusts.Occupational hazards include exposure to 
cadmium, toluene gas in plastic plants, construction and utility work. 
Recurrent respiratory tract infections: 
Lower respiratory infections in childhood is also postulated as a risk 
factor for the development of COPD.25,26,27 This is due to the permanent 
 
 
damage or impaired lung growth. The risk of reduced lung function in future 
is high. 
Airway hyperresponsiveness: 
Many patients with COPD also experiences airway 
hyperresponsiveness28,29,30 which is a common association in bronchial 
asthma. The rate of reversibility in the degree of obstruction with 
bronchodilators is less than 15 %. 
GENETIC BACKGROUND: 
Aggregation of cases in families suggest that there is an established 
role for genetic factors in the pathogenesis of COPD. Occurrence of early 
onset COPD and decrease in the maximal expiratory flow rate among the 
nonsmoking first degree relatives of COPD supports the above said 
statement.   
Polymorphism of genes involving protease - antiprotease balance, 
antioxidant function, inflammation and immune responses has been 
proposed. 
Alpha 1 antitrypsin  is a major antiprotease enzyme in the serum .31 
The synthesis of  alpha one antitrypsin is regulated by a gene on 
chromosome 14q32. 
 
 
The most common deficient allele is PiZZ phenotype which is due to 
amino acid substitution of 342 Glutamic acid to lysine.32 
This change results in spontaneous polymerization of polypeptide and 
impaired release of alpha one antitrypsin from the liver. 
This deficiency is rare in Asian and African descendants, whereas 
more common in European population (1 in 2000 to 1 in 7000). 
 About 2 % of the patients with emphysema is due to alpha one 
antitrypsin deficiency.33 
Patients usually presents with premature bronchiectasis or chronic 
bronchitis. 
More than 80 percent of the patients have autosomal recessive 
inheritance.  Decline in FEV1 is around 100-130ml per year for smokers , 
50-80ml per year for exsmokers and nonsmokers.  
Panacinar emphysema is the most common type seen with 
predominant involvement of lower lobes of the lung. Smoking is an 
important cofactor in the development of COPD in patients with alpha one 
antitrypsin deficiency. They are also at an increased risk for cirrhosis of 
liver. 
 
 
 
PATHOLOGY: 
Pathological changes are seen in larger and smaller airways as well as 
in terminal bronchioles. Small airways are considered as important site of 
airflow limitation.34,35Various reasons which are responsible for narrowing 
of lumen of small airways are goblet cell hyperplasia ,edema , mucosal and 
submucosal inflammatory cells, peribronchial fibrosis, smooth muscle 
hypertrophy and mucus plugs.39 
In larger airways hypertrophy of submucosal mucous glands is seen. 
 Reid index is a measure of  thickness of  submucous glands to that of 
bronchial wall . In normal individuals the range is between 0.44 to 0.60, 
whereas in chronic bronchitis it is between 0.34 -0.53. 
Emphysema starts as an increase in both number as well as size of the 
alveolar fenestrations and results in destruction of the septa. It also destroys 
the attachments of the septa to the terminal bronchioles. 
The site of destruction varies in different types of emphysema. In 
centriacinar it predominantly involves respiratory bronchioles, whereas 
panacinar involves both central as well as peripheral bronchioles. 
 
 
 
 
 
PATHOGENESIS AND PATHOPHYSIOLOGY: 
Central to the  pathogenesis is found to be an enhanced  inflammatory 
process in response to inhaled particles and gases.36,37The pathogenesis  
includes various processes 
1. Increased airway inflammation40 
2. Increased protease burden-decreased anti protease function38 
3. Oxidant –anti oxidant imbalance (oxidative stress) 
4. Defective lung repair mechanisms 
Chronic exposure to smoke, fumes, dusts results in inflammatory 
recruitment of inflammatory cells within the terminal air space of lungs. 
These cells results in destruction of walls and extra cellular matrix of the 
lungs. 
Persistent reduction in the forced expiratory flow is the defining feature in 
case of COPD. 
Other typical features are   
1.Increased airway resistance   
2.Increased residual volume  
 
 
3. Increased RV/TLC   
4.Decreased inspiratory capacity  
5.Maldistribution of ventilation. 
Airflow obstruction: 
Balance between the elastic recoil of the lungs that promote the flow 
and the resistance of airway that limits the flow contribute to the airflow 
during forced exhalation. 
As the cross sectional area of the airway falls due to destruction the 
resistance increases, and the expiratory flow also decreases as the volume 
occupied decreases due to loss of elastic recoil and loss of radial traction of 
airways. 
In early stages the abnormality in airflow limitation is seen only at 
lung volumes at or below the FRV. 
It is possible to distinguish between emphysema and small airway 
pathology only theoretically,  since emphysema is due to decreased elastic 
recoil and small airway disease is due to increased airway resistance as a 
cause of reduced  FEV1. 
Clinically it is more difficult to differentiate between these two as it 
coexist in most of the patients. 
 
 
FEV1 correlation is better with small airway pathology when 
compared to emphysema. 
FEV1 remains a good predictor  because  PaO2 usually remains near 
normal till FEV1 decreases up to half of the predicted level. Very low levels 
of FEV1 can be still associated with normal PaO2. 
Usually PaCO2 is not elevated until the FEV1 is less than 25% of 
predicted value. 
MALDISTRIBUTION OF VENTILATION: 
COPD is a heterogenous disease, since it affects both airways as well 
as lung parenchyma.This heterogeneity can be revealed by xenon gas 
ventilation. 
MIGET classification of  COPD: 
Type A- high ventilation perfusion ratio-emphysema 
Type B-low ventilation perfusion- chronic bronchitis 
But most of the COPD patients will have neither type A or B, they 
will have both high and low perfusion  areas. 
The reduction of  PaO2 is mainly due toVentilation/Perfusion 
mismatch, shunt is minimal. So moderate concentration of O2 can correct 
 
 
the hypoxemia in COPD. If it is not getting corrected then other causes such 
as pulmonary embolism,shunting should be considered. 
HYPERINFLATION: 
It is defined as 
1.increased FRV. 
2.increased residual volume to total lung capacity. 
3.decreased inspiratory capacity to total lung capacity. 
Though hyperinflation may be some times beneficial, adverse effects 
are more. 
The adverse effects are due to  
1. Loss of apposition zone,between the diaphragm and abdominal 
wall,so pressure cannot be transmitted for effective respiration. 
2. Flattened short diaphragm muscles are not able to generate 
inspiratory pressures. 
3. Increased tension required to generate transpulmonary pressure. 
In those with hyperinflation the inspiratory capacity will be reduced. 
IC can be used as a prognostic significant value independent of the 
FEV1. 
 
 
Recently lung cells senescence has been involved in the pathogenesis  
of emphysema. 
PATHOPHYSIOLOGY OF EXACERBATION: 
Exacerbation of COPD are associated with a further increase in 
inflammatory response  in the lungs predominantly involving neutrophils. 
These response may be triggered by bacterial or viral infection or  by 
pollutants. 
This worsens the existing ventilation perfusion mismatch leading to 
respiratory failure and death. 
LESIONS OF THE VESSELS IN COPD: 
There is no specific change in the vessel wall of the patient with 
COPD,  sometimes atheromata may be seen. 
Pulmonary hypertension develops during late phase of the disease. 
These changes are mostly secondary to vascular shunting and increased 
intimal fibrosis. 
PULMONARY CIRCULATION IN COPD: 
In later stages of the disease pulmonary arterial hypertension 
develops, along with the development of  hypoxemia, hypercapnia. It is the 
 
 
important complication of COPD. It is associated with development of right 
ventricular hypertrophy and worse prognosis. 
ABNORMAL BLOOD GAS TENSION: 
HYPOXEMIA: 
Since hypoxemia is a potent vasoconstrictor , PaO2 has an inverse 
relationship with the development of  pulmonary arterial hypertension. 
Increasing arterial desaturation worsens the pulmonary pressure. Pulmonary 
artery pressure rises suddenly during REM sleep because of the relative 
hypoxemia and recurrence of this nocturnal pulmonary hypertension is 
inturn responsible for the changes in pulmonary hypertension. 
HYPERCAPNIA: 
There exists a direct relation with the PaCO2 and pulmonary artery 
pressure. This is probably due to hyperventilation induced hypercapnia or 
hypoxia induced pulmonary hypertension. 
ACIDEMIA: 
Combination of  both hypoxia and hypercapnia results in pulmonary 
hypertension in patients with  COPD. So for given PO2 the mean Ppa is 
higher with increasing hydrogen concentration. 
 
 
 
EFFECTS OF ABNORMAL PULMONARY MECHANICS: 
Changes in the pulmonary resistance results from increase in airway 
resistance matching with decrease in FEV1. 
EFFECTS OF INCREASED CARDIAC OUTPUT: 
Even minor increments in the cardiac output that occurs during 
exercise significantly rises the pulmonary arterial pressure. 
EFFECTS OF BLOOD VISCOSITY: 
Chronic hypoxemia which in turns develops polycythemia due to increased 
production of erythropoietin contributes to increasing  blood viscosity 
thereby increasing pulmonary arterial hypertension. 
ROLE OF PULMONARY ENDOTHELIUM: 
As with any other disorder, the endothelial dysfunction plays a major 
role in PAH. This results in reduction in the NO synthesis or release in 
response to hypoxia. So the protective role of nitric oxide in preventing the 
rise of pulmonary vascular tone is lost in COPD. 
Circulating levels of endothelin are increased in patients with 
emphysema and associated pulmonary hypertension. 
Changes in pulmonary circulation mainly affects the peripheral 
pulmonary arteries in COPD patients. Initial change will be intimal 
 
 
hypertrophy due to longitudinal deposition of smooth muscle and in those 
with persistent pulmonary hypertension there will be a medial hypertrophy. 
Pulmonary thrombosis occurs secondary to peripheral inflammation . 
PULMONARY HEMODYNAMICS IN COPD: 
It depends on the severity of the disease. In case of mild disease 
without blood gas changes pulmonary pressure is normal or minimally 
elevated when measured at  rest, but abnormal elevation occurs in response 
to exercise. 
Almost cardiac output will be normal in the patients with COPD as 
are the right atrial and right ventricular end diastolic pressure. 
In clinically stable cases of COPD the pulmonary pressures will be 
modestly elevated. 
CONSEQUENCES OF PULMONARY HYPERTENSION IN COPD: 
Chronic bronchitis and emphysema coexist pathologically.  
In case of chronic bronchitis which is otherwise called as type B or 
blue bloaters  develop pulmonary hypertension relatively early in the course 
of the disease.        
In contrast in those with emphysema the blood gas analysis will be 
normal but clinically will have severe breathlessness and almost do not 
 
 
develop pulmonary hypertension or develops only in the late stage of the 
disease. 
NATURAL HISTORY OF PULMONARY HYPERTENSION: 
In COPD patients the elevation of the pulmonary pressure will be less 
and slow, the pressure will almost never reach the higher levels as like that 
of  primary pulmonary hypertension. 
Weitzenblum found that a change of 3mm hg in pulmonary pressure 
per year and 1/3 of the patients develop increase in pulmonary pressure of 
5mm in 5 years. 
Survival rate in patients with pulmonary hypertension was 40% 
compared to 72% in those with normal pulmonary pressure. 
COR  PULMONALE: 
Cor pulmonale is defined as right ventricular hypertrophy and 
dilatation secondary to diseases of the lung parenchyma/vasculature or both. 
The prevalence of cor pulmonale is higher in patients with 
hypercapnia,  hypoxemia,  polycythemia   and in those with reduced FEV1. 
In clinically stable patients inspite of elevated pulmonary  arterial 
pressure the right ventricular contractility is maintained. 
 
 
In contrast, in patients with respiratory failure the right ventricular 
contractility is decreased . Edema in the late stages of the disease may not 
be entirely due to right ventricular failure, other causes should be ruled out. 
Due to hypoxemia and hypercapnia there will be a reduction in the 
renal function due to decreased blood flow which leads to changes in salt 
water balance. Decreased blood flow may be due to inappropriate arginine 
vasopressin levels or neurally mediated catecholamine release. 
Thus the development of peripheral edema in COPD involves a 
complex hemodynamics with multiple interactions. 
Other grave risk factors include marked hypoxemia, increased 
pulmonary artery pressure and decrease in carbon monoxide transfer. 
In patients with right ventricular failure , the prognosis will be poor 
and mortality rate will be high up to 65-80%. 
Clinical symptoms: 
Most patients are usually smokers with almost atleast 20  pack years. 
Patients usually present in 5th decade of life. 
Chronic bronchitis manifest as cough with expectoration, wheeze, 
breathlessness with exacerbation of symptoms during winter. 
 
 
Sputum may be mucoid or mucopurulent. Sputum may be purulent 
even in the absence of superimposed infection because of large amount of 
neutrophils. 
Pure emphysema presents as dyspnea and other symptoms such as 
wheezing, cough with  expectoration are less common.  
Except in rare cases of hereditary emphysema , chronic bronchitis and 
emphysema often coexists. The common cause of mortality in patients with 
emphysema is respiratory failure. 
 Emphysema patients will have near normal PaO2 and PaCO2 for that 
reason they are called as pink puffers. 
  Patients with chronic bronchitis usually develop cor pumonale and 
hypoxia . They are called as blue bloaters. 
Other major symptoms includes weight loss and exercise limitation . 
Progressive damage of the alveolar wall may culminate in the 
formation of bullae. 
Chronic hypoxemia may lead to peripheral muscle atrophy. 
 
 
 
 
 
Physical signs: 
 In early stages of the disease , the physical examination may be 
entirely normal.In later stages they will be emaciated, cyanosis and 
polycythemia may be noted.41 
Peripheral edema and elevated JVP  are seen in cases associated with 
cor pulmonale. 
Patients sometimes adopt a peculiar tripod posture to increase the 
chest wall movements by facilitating the use of accessory muscles of 
respiration. 
Chest wall is often barrel shaped with kyphosis, and increased 
anteroposterior diameter, horizontally aligned ribs,with prominent sternal 
angle and wide sub costal angle. 
Patients adopts pursed lip breathing during expiration in an attempt to 
decrease the collapse of airways. 
Chest wall expansion is reduced and in severe cases there is a 
paradoxical indrawing of costal margins due to pull of low flattened 
diaphragm. 
On auscultation there will be a prolonged phase of expiration with 
fine inspiratory crackles. 
 
 
Investigations: 
RADIOLOGY: 
Chest xray: 
In chronic bronchitis, parallel line opacities are seen which are 
indicative of bronchial wall thickening.42,43 
The radiographic features of emphysema includes: 
 Overinflation of the lungs 
 Low flattened diaphragm- the border of diaphragm lies below the 7th 
rib. 
 Height of the lung is greater than 30 cm 
 An obtuse costophrenic angle may be seen. 
 Vertical and narrowed heart shadow is seen (tubular heart). 
 Reduction in size and number of pulmonary vessels in the periphery 
of the lung. 
 Hilar vessels are enlarged. 
 In lateral chest xray there is an increase in the retrosternal 
space(>2.54 cm). 
 Presence of bullous lesions is an important evidence of emphysema. 
Bullae may present as a stable lesion. Sometimes, it may enlarge 
massively sufficient enough to cause the collapse of the entire lung.It 
 
 
is called as vanishing lung syndrome. Pneumothorax is the important 
differential diagnosis. Bullae may rupture to produce secondary 
pneumothorax. 
 In fluoroscopy , low and flat diaphragm is seen. A paradoxical 
upward movement during inspiration may be noted. 
Computed tomography: 
It  has greater sensitivity and specificity in the diagnosis of 
emphysema when compared to chest xray.44,45It is helpful in the evaluation 
of  bullous lesions of the lung. It is seen as areas of low attenuation without 
obvious margins.Attenuation and pruning of the vessels can be detected. 
A decrease in the CT lung density signifies the presence of 
microscopic emphysema. 
Bronchograms may show irregular, narrowed and distorted bronchi. 
SPIROMETRY :46 
It is the most important test in assessing the air flow limitation. It is 
helpful in arriving at a diagnosis of COPD and also in predicting the 
severity of the disease  and in further follow up of patients. 
The major abnormalities include reduction in FEV1 and in the ratio of 
FEV1/FVC . 
 
 
 The presence of a post bronchodilator FEV1 <80% along with  
FEV1/FVC ratio <0.7 indicates the presence of airflow obstruction that is 
not totally reversible. 
Assessment  of  reversibility to bronchodilators is done in COPD 
patients to differentiate it from bronchial asthma . It is also important in 
identifying the post bronchodilator FEV1 which is a better predictor of the 
prognosis. 
According to ATS  and GOLD guidelines a change in FEV1 of more 
than 200 ml and a percentage change of more than 12% is considered as 
significant reversibility but according to British thoracic society guidelines 
change in FEV1 50% above the base line is considered significant. 
Around  30%  of  COPD  patients may show significant reversibility 
with  bronchodilator therapy. 
LUNG VOLUMES: 
Static lung volumes like total lung capacity, residual volume, 
functional residual capacity and the ratio of  RV/TLC are measured in 
COPD patients. 
It is used to assess the degree of hyperinflation and gas trapping. 
The lung volumes are increased in COPD patients 
 
 
Two methods adopted are 
1. Helium dilution technique48 
2. Body plethysmography – it is more reliable since it measures poorly 
ventilated areas. 
Gas transfer for carbon monoxide: 
A low DL co is present in COPD patients. 47 
Single breath technique is routinely used method that uses helium 
dilution technique. 
Helpful in differentiating COPD patients from asthmatic patients 
since a low DLco rules out asthma. 
 
Arterial blood gas analysis: 
Useful in assessing degree of hypoxemia and hypercapnia. 
  Usually seen once FEV1< 50% 
Blood gas abnormalities may occur during exercise and sleep and 
during exacerbations. 
Though pulse oximetry is commonly used , it is not to be considered 
as a replacement for ABG. 
 
 
 
EXERCISE TEST: 
1. Progressive symptoms limited exercise test: 
It  requires the patient to perform exercise on a treadmill or a cycle 
until symptoms prevent him. 
The maximum test is defined as heart rate of  >85% of the predicted 
or ventilation  >90% predicted.  
2. Self paced exercise test: 
- 6 minute walk test is the frequently used test49 
-used only in patients with moderately severe COPD 
-it is useful in predicting the longevity in severe COPD patients 
3. Steady state exercise test: 
Not routinely done in COPD patients 
Sleep studies: 
-For identifying the nocturnal hypoxemia 
-useful in patients with pulmonary hypertension, corpulmonale and in 
case of associated sleep apnea syndrome. 
 
 
Other variables to be monitored: 
-hematocrit:  to screen for polycythemia which develops in response 
to chronic hypoxemia. 
- complete blood count to evaluate for anemia for chronic disease. 
-measurement of alpha antitrypsin levels is indicated in patients with 
early onset of emphysema less than 45 years of age and those with family 
history of emphysema. 
MANAGEMENT OF COPD: 
1.NON PHARMACOLOGICAL: 
Cessation of smoking50 
It is  the single most  cost effective approach to reduce the exposure 
to reduce exposure to risk factors. 
Health education regarding the risk factors and complications related 
to the disease. 
Legislation to form smoke free schools , public facilities and work 
environments should be developed. 
Comprehensive tobacco control policies and programs with clear 
consistent non smoking messages should be delivered through a proper 
channel. 
 
 
2.PHARMACOLOGICAL 
1.Bronchodilators : 
They are useful in COPD to relieve reflex bronchoconstriction and to 
combat the increased muscle tone.51 
Rate of decline of FEV1 decreases with the  use of bronchodilators. 
Theophylline: 
Apart from its bronchodilator action it has also beneficial effect on 
muscle fatigue and improves the outcome significantly. It is also a mild 
respiratory stimulant which is useful in patients with decreased respiratory 
drive. 
Non respiratory effects includes increased ciliary motility and anti 
inflammatory property. 
Dose of theophylline in non smoker is 10-12mg/kg/day in divided 
doses. 
In smokers higher doses up to 20 mg/kg/day are useful whereas dose 
reduction is needed in patients with hypoxemia and in liver disease. 
 
 
 
 
2.SYMPATHOMIMMETIC BRONCHODILATORS: 
Beta agonist52 remains corner stone treatment in obstructive airway 
disease . 
Approach is to increase the dose and frequency of the beta agonist or 
anticholinergic or both. 
3.CORTICOSTEROIDS: 
Used in patients with severe exacerbation.53 
Dose usually used is around 30-40mg prednisolone for 14 days 
Inhaled steroids are not as effective as oral steroids in exacerbation but can 
be used in prevention of exacerbation. 
4.ANTIBIOTICS: 
The common organisms implicated in these patients are streptococcus 
pneumonia, haemophilus influenza and Moraxella. So an antibiotic 
coverage including oral aminopenicillin, macrolide (erythromycin, 
azithromycin, clarithromycin) and tetracycline antibiotics are 
recommended.54 
 
 
 
 
 
5.OXYGENTHERAPY: 
Oxygen may be administered via ventury mask or nasal prongs. 
It is used to treat hypoxemia in acute exacerbation. Aim of the 
therapy is to prevent hypoxemic tissue damage. 
In acutely ill patients the goal of oxygen therapy is to improve pao2  
to  more than 60mm Hg. 
In chronic lung disease, long term oxygen supplementation has 
increased the longevity as supported by the studies like nocturnal oxygen 
therapy trial in USA55and MRC working party on long term domiciliary 
oxygen therapy  in UK. 
Greater benefit is observed if oxygen therapy is administered for 
atleast 18 hours per day. 
6.ALPHA ONE ANTITRYPSIN  AUGMENTATION  THERAPY: 
It is used in young non smokers with severe alpha 1 AT deficiency 
associated emphysema. 
7.SMOKING CESSATION  THERAPY: 
            Nicotine replacement therapy (gum, tablets, transdermal patch, 
lozenges, nasal spray) 
 
 
Anti depressants  like bupropion, nortryptiline increases the long term 
quit rates. 
            Recently varenicline, a nicotinic acetylcholine receptor partial 
agonist helps in relieving withdrawal symptoms of nicotine dependence. 
NON INVASIVE VENTILATION: 
It is administered via nasal or full face mask without the need of 
endotracheal tube. It is indicated in patients with hypercapnic respiratory 
failure  during exacerbations. 
Most common mode of delivering is pressure cycled bilevel positive 
air way pressure.56It is contraindicated in patients with severe acidemia and 
hypoxemia, unconscious and hemodynamically unstable patients. 
INVASIVE VENTILATION: 
Main indication is severe hypoxia with respiratory academia and in 
unconscious patients during acute exacerbation of COPD.  
SURGERY: 
1.LUNG VOLUME REDUCTION  SURGERY : 
  It involves removal of 20-30 % of the lung bilaterally mainly from the 
apices.58 
 
 
 
INDICATIONS: 
Emphysema predominantly involving the upper lobes and low 
exercise capacity 
CONTRAINDICATION: 
Patients with FEV1 <20% , diffusion capacity less than 20%, diffuse 
homogenous opacity on HRCT. 
Patients outcome will be poor in those who underwent lung volume 
reduction surgery in the lower lobe predominant disease. 
NON SURGICAL LUNG VOLUME REDUCTION: 
Implantation of one way valves using bronchoscope which induces 
atelectasis. 
Removal of  bullae results in decrease in residual volume and increase 
in vital capacity. 
2.Lung transplantation: 
Among the major causes of lung transplantation COPD  ranks  the 
first indication. 
It contributes nearly 40% of all lung transplant and 50% single lung 
transplant. 
 
 
Most common  indication for lung transplantation in COPD is severe 
hypoxemia, FEV1 less than 25% in young patients less than 45 years 
without other comorbidities. 
Absolute contraindication : 
Current smoking, malignancy, major organ failure or chronic hepatitis 
B or hepatitis C. 
Relative contraindication: 
Poor nutritional status , Mycobacterial infections, severe osteoporosis 
and suboptimal psychosocial support. 
Treatment of  Cor pulmonale: 
First line of treatment is to provide continuous oxygen support to 
overcome  hypoxemia and  diuretics for peripheral edema. 
In patients with atrial fibrillation digoxin is used, benefits of Calcium 
channel blockers  as vasodilators is still controversial since it worsens the 
hypoxemia. 
PULMONARY  REHABILITATION: 
The aim is to optimize the physical and the social performance of the 
patients .57 
It includes 
1.Education 
2.Chest physiotherapy:  
 
 
 
It consists of postural drainage, chest vibration and percussion. 
Pursed lip breathing which was first observed by Laennec to be taught 
in patients with COPD.It slows down the expiration and  help in preserving 
the positive airway pressure and avoiding collapse of the lungs. 
3.Exercise training includes breathing and relaxation techniques. 
4.Providing psychosocial support to the patients. 
Other supportive treatments: 
VACCINES: 
Influenza vaccines can reduce the serious illness and mortality rate by 50% 
in  COPD patients. 
Pneumococcal polysaccharide vaccine is commonly recommended 
for patients above 65 years .It has been found to lower the incidence of 
community acquired pneumonia. 
 
 
MUCOLYTICS: 
     Few patients  with viscous sputum may benefit from mucolytics. 
Ambroxol, carbocysteine and iodinated glycerol are commonly used. 
 
 
 
 
 
CRP An inflammatory marker 
Inflammation is considered as a protective response of vascular 
connective tissue to external injury or stimuli . It is usually associated with 
the release of inflammatory mediators like prostanoids, vasoactive amines, 
cytokines and reactive oxygen species. 
The term acute phase response (APR) 59is described to encompass all 
the changes occurring in various organs in response to systemic 
inflammation. It is a non specific response initiated by various stimuli like 
burns, surgical or physical trauma, irradiation and infection. Cytokines 
mediating this acute phase response are tumour necrosis factor alpha, 
interleukin 1 and interleukin 6 .One of the most fascinating fact of the APR 
isrise in acute phase proteins synthesized in the liver. 
ACUTE PHASE PROTEINS: 
POSITIVE ACUTE PHASE PROTEINS: 
1.Protease inhibitors such as anti chymotrypsin and alpha 1 anti trypsin 
2.Coagulation proteins such as fibrinogen, plasminogen, prothrombin and 
factor 8. 
3.Various complement proteins such as C2,C3,C4,C5,C1esterase inhibitor 
and plasminogen. 
 
 
4.Transport and storage proteins such as haemopexin, ceruloplasmin,  
ferritin and  haptoglobin.  
5.Other positive APR ‘s are CRP, procalcitonin,  serum fibronectin, alpha1 
acid glycoprotein (orosomucoid), mannose binding lectin and serum 
amyloid protein. 
NEGATIVE ACUTE PHASE PROTEINS: 
1.Albumin 
2.Pre albumin 
3.Transthyretin 
4.Transcortin 
5.Transferrin 
6.Antithrombin 
CRP is a biological substance which was known as acute phase 
reactant for long back, originally described 70  years ago . Now it is used as 
an inflammatory marker. It was named so because of its interaction with 
phosphoryl choline and lipoteichoic acid found on pneumococcus. 
CRP  is the best known of the acute phase protein since it is regularly 
used as a marker of systemic inflammation in clinical settings. They may 
increase from 1 mcg/ml to 500mcg/ml in severe inflammation.60 
 
 
It is released in excess amount within 6 hours of an acute 
inflammatory stimulus. Doubling time in plasma occurs atleast every 8 
hours.  It attains the peak concentration after 50 hours. 
 The plasma concentration can fall almost as rapidly as 5-7hours 
plasma half life after appropriate treatment or removal of the inflammatory 
stimulus. 
CRP is a member of the pentraxin family of proteins. It also includes 
homologues of  similar size proteins such as serum amyloid protein (SAP)or 
larger proteins such as long pentraxins (PTX3) . 
C-reactive protein specifically binds to phosphocholine present on the 
cell membrane of microbes and it activates the classical complement 
pathway and inturn opsonizes the ligands for phagocytosis. It down 
regulates the polymorphs and also neutralizes the platelet activating factor.  
Although in the clinical context elevation of CRP is suggestive of 
infection or inflammation, it may also occur with various other conditions 
like obesity, malignancy and renal dysfunction. Conversely, a lack of 
elevation of CRP is seen during flairs of systemic lupus erythematosus as 
well as in patients with hepatic failure. 
 
 
 
 
CONDITIONS WITH ELEVATED CRP: 
1.Bacterial infections such as pyelonephritis, meningitis and endocarditis. 
2.Inflammatory diseases such as Rheumatoid Arthritis , Psoriatic Arthritis , 
Reiters Disease, Crohns Disease , Ankylosing Spondylitis And Familial 
Mediterranean Fever .  
3.Malignancies such as lymphoma and sarcoma . 
4.Necrotic infection such as acute pancreatitis, myocardial infarction and 
tumor embolization . 
5. Other nonspecific conditions such as burns and fractures . 
Levels of C-reactive protein in some conditions remained normal 
inspite of active inflammation which includes, 
1. SLE 
2. Dermatomyositis 
3. Systemic sclerosis 
4. Graft versus host disease 
5. Leukaemia 
6. Ulcerative colitis 
 
 
 
The reason for this selective failure of raise in CRP in the above said 
conditions is unknown. 
CRP and cardiovascular disease: 
Atherosclerosis is the process underlying cardiovascular disease.It is 
partly responsible for the chronic low level inflammation of the vascular 
endothelium . Inflammation is obvious at the site of plaque rupture.64 
Several studies like MRFIT 65and WHI study in postmenopausal 
women support the above fact. 
Apart from its use as an inflammatory marker it is also used in  
1.Assessing the response to treatment in conditions such as rheumatoid 
arthritis where there will be a dramatic fall in CRP level following 
treatment. 
2.To differentiate bacterial and viral infections 
    (usually elevated in bacterial infection) 
3. To avoid confusion between a disease flare and super infection in 
conditions such as systemic lupus erythematosus. 
CRP levels remains unaltered by antipyretic or any other 
thermoregulatory factors. So it can be used as an adjunct to use temperature 
chart in clinical practice. 
 
 
Recent works done in relation with cognitive assessment  reveals that  
levels of CRP are high in those with impaired cognition.61 The exact 
etiology for this is unknown. Further work is warranted in this field. 
High sensitivity CRP: 
Though both measure the same substance in blood, Ultra sensitive or 
high sensitivity CRP 66refers to the measurement of small changes in CRP 
concentrations which the standard test used for measuring CRP tend to miss. 
Standard test for CRP measures only values more than 10  mg/L . 
Values less than 10mg/L can be measured only by hs-CRP.63 
Estimation : 
Though it was an inflammatory marker initially it is not used widely 
because of  the unavailability to measure low values which make the results 
insensitive. 
Previously it was measured by ELISA. But now, at present highly 
sensitive commercial kits like nephelometry and turbidometry are available 
which make the assay highly sensitive. 
  
 
 
 
MATERIALS AND METHODS 
This study was conducted at the Department of medicine and thoracic 
medicine  at Thanjavur medical college hospital during   OCTOBER 2011-
NOVEMBER 2012. 
TOTAL NUMBER OF PATIENTS INCLUDED IN THE STUDY : 
70  patients (both males & females). 
STUDY METHOD: 
      This is a cross sectional study. 
GEOGRAPHIC DISTRIBUTION: 
Patients included in this study were from urban  and rural areas of 
Ariyalur, Perambalur , Thanjavur, Thiruvarur  and Pudhukottai districts. 
INCLUSION CRITERIA: 
1. Age limit between  30-80 years of both sexes 
2. Clinical symptoms like cough/sputum production/breathlessness with 
or without swelling of legs of more than 2 years duration. 
3. Clinically diagnosed cases of COPD. 
 
 
4. Spirometrically confirmed cases of COPD and post bronchodilator 
values of                                                                                                                     
FEV1 <80% 
FEV1/FVC <0.7 
Reversibility  from obstruction <15% 
FVC- Forced Vital Capacity 
FEV1- Forced Expiratory Volume in 1 second 
EXCLUSION CRITERIA: 
Patients with past  history of the following diseases were excluded 
from the study 
1.Bronchial Asthma 
2.Pulmonary Tuberculosis 
3.Systemic Hypertension 
4.CAHD 
5.Sleep Apnoea Syndrome 
6.Connective tissue diseases like RA 
7.Chronic renal failure 
 
 
PROCEDURE: 
Proforma was prepared based on the above said criteria to meet the 
objectives of the study 
Each patients were evaluated as follows 
1. Detailed history as per the proforma 
2. Smoking history in detail: 
Total number of  years smoked 
Cigarette/beedi 
Pack years: Number of cigarettes per day/20   × Number of years of 
smoking 
3. Clinical examination  with  detailed examination of  respiratory 
system. 
4.Chest  X ray  
5.Sputum AFB 
6.ECG 
7.CT THORAX 
 
 
 
 
6.SPIROMETRY 
Spirometry was done in all cases and staged accordingly based on 
GOLD criteria 
FVC- FORCED VITAL CAPACITY: 
It is defined as the volume of air that can be forcibly exhaled after a 
maximal inspiration expressed in liters. 
FEV1-FORCED EXPIRATORY VOLUME IN 1 SECOND: 
It is the volume of air expelled in the first second from the start of maximum 
expiratory effort of the forced vital capacity (expressed in liters or % of 
predicted). 
FEV1/FVC: 
It is the percentage of forced vital capacity which is expelled in the first one 
second of maximal inspiratory effort. 
HIGH SENSITIVITY  CRP ESTIMATION: 
The hs-CRP levels were measured by latex enhanced nephelometry 
and are interpreted in the ranges of less than 3 mg /L as normal and low risk 
and  >3mg/l as high risk. 
 
 
 
 
NEPHELOMETRY: 
It  is defined as the detection of light energy scattered towards a 
detector that is not in the direct path of transmitted light. Commonly 
available nephelometers are those which measure the scattered light at right 
angles to the incident light. 
It is the commonly used technique for protein assays such as 
lipoprotein a, C-reactive protein, rheumatoid factor, anti streptolysin O and 
immunoglobulins. 
Other method which is less sensitive than nephelometry is 
turbidometry. The detection limit of nephelometry is 10mcg/ml where as for 
turbidometry it is 20-30 mcg/ml.  
The main aim of our study is to assess hs-CRP as a cost effective 
auxiliary marker other than spirometry in determining the severity of 
COPD. 
  
 
 
RESULTS AND OBSERVATION 
Results of our study were tabulated into different variates and 
incidence of each variate was calculated. 
                                                   TABLE 1 
 
 
 
 
 
 
 
From the above table it is observed that majority of the cases included in our 
study belongs to 60-70 years of age. 
 
 
 
 
Particulars 
No.of patients 
(n=70) 
Percentage 
(100%) 
31 to 40yrs 6 8.6 
41 to 50yrs 15 21.4 
51 to 60yrs 20 28.6 
61 to 70yrs 24 34.3 
71 to 80yrs 5 7.1 
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SEX DISTRIBUTION 
TABLE 2 
 
It is inferred that majority of the patients included in our study are of male 
sex. 
Male to female ratio is approximately 8:2 
 
  
SEX DISTRIBUTION
MALE
FEMALE
SEX 
 
NO OF  PATIENTS 
 
Percentage 
(100%) 
Male 54 77.1 
Female 16 22.9 
  
GEOGRAPHICAL DISTRIBUTION -TABLE 3 
 
 
From the above table it is inferred that 50 out of seventy cases were from 
rural  areas  constituting 71% of  the total cases. Remaining 20 cases from 
urban  areas  constitutes 29% of  the total cases. 
 
 
 
 
AREA
RURAL
URBAN
AREA NO. OF 
CASES 
MALE FEMALE % 
RURAL 50 40 10 71.42 
URBAN 20 14 06 28.58 
TOTAL 70 54 16 100 
54 
 
 
 
RISK FACTORS 
1.SMOKING 
ACTIVE SMOKING – TABLE 4 
Pack years 
No. of patients 
(n=70) 
Percentage 
(100%) 
Non smokers 22 31.4 
10 to 20 2 2.9 
21 to 30 36 51.4 
31 to 40 10 14.3 
 
 
Active smoking is the predominant  risk factor in our study population 
which constitutes approximately 70% of the total population 
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TABLE 5 
PASSIVE SMOKING 
Particulars 
No. of   patients 
(n=70) 
Percentage 
(100%) 
Absent 63 90.0 
Present 7 10.0 
 
Passive smoking was observed in 7 cases out of  the 70 cases who were all 
females. 
 
 
 
 
PASSIVE SMOKING
Absent
Present
57 
 2.  CHRONIC RESPIRATORY INFECTION  
TABLE 6 
 
 
 
 
Chronic respiratory infection was present in 54% of the study population
 
 
 
 
29
30
31
32
33
34
35
36
37
38
39
PRESENT ABSENT
CRI
PRESENT
ABSENT
Particulars 
No. of  patients 
(n=70) 
Percentage 
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Absent 32 45.7 
Present 38 54.3 
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3.ALLERGY 
                                  TABLE 7 
Particulars 
No. of patients 
(n=70) 
Percentage 
(100%) 
Absent 58 82.9 
Present 12 17.1 
 
Allergy constituted 17% of the risk factor in our study 
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4.AIR POLLUTION 
                                 TABLE 8 
Particulars 
No. of patients 
(n=70) 
Percentage 
(100%) 
Absent 58 82.9 
Present 12 17.1 
 
Air pollution constituted 17% of the risk factor in our study.
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DURATION OF THE DISEASE 
                             TABLE 9 
Particulars 
No. of patients 
(n=70) 
Percentage 
(100%) 
2 to 5yrs 4 5.7 
6 to 10yrs 7 10.0 
11 to 15yrs 23 32.9 
16 to 20yrs 29 41.4 
20yrs & above 7 10.0 
From the above table it is observed that majority of patients suffered for 
more than 15 years. They constitute around 51% of the total population. 
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DISTRIBUTION OF SYMPTOMS 
TABLE 10 
 
SYMPTOMS 
 
NO. OF PATIENTS 
 
PERCENTAGE(%) 
 
Cough 
 
70 
 
100% 
 
Cough with sputum 
 
62 
 
88.6% 
 
Wheeze 
 
58 
 
82.9% 
 
Breathlessness  
 
62 
 
88.6% 
 
Swelling of both legs 
 
05 
 
7.1% 
 
From the above table it is noted that the major symptom in our patients was 
cough which was present in almost every patient (100%) 
  
  
 
 
DISTRIBUTION  OF  SYMPTOMATOLOGY 
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DISTRIBUTION OF CLINICAL SIGNS 
  TABLE 11 
 
From the above table it is inferred that active accessory muscles of 
respiration (intercostal indrawing) was the major clinical sign observed in 
50% the study  population. 
 
 
 
 
 
SIGNS NO.OF PATIENTS PERCENTAGE(%) 
Cyanosis 08 11.4% 
Polycythemia 11 15.7% 
Raised JVP 05 7.1% 
Pursed Lip Breathing 10 14.3% 
Pedal Edema 05 7.1% 
Accessory Muscles 
Working 
35 50% 
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 TABLE 12 
 
 
 
 
 
 
In our study obese patients with BMI above 31 contribute about 14.3% and 
the remaining are with BMI below 25. 
 
 
 
 
No.of patients
Below 25
31 & above
BMI 
No.of patients 
(n=70) 
Percentage 
(100%) 
Below 25 60 85.7 
31 & above 10 14.3 
66 
 
 
DISTRIBUTION OF CASES AS PER GOLD STAGING 
TABLE 13 
GOLD STAGING FEV1% 
No. of  patients 
(n=70) 
Percentage 
(100%) 
Stage1 
mild 
>80% 05 7.1% 
Stage 2  
moderate 
50-80% 06 8.6% 
Stage 3 
Severe 
30-50% 39 55.7% 
Stage 4 
Very severe 
<30% 20 28.6% 
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 DISTRIBUTION OF hs-CRP IN OUR STUDY 
TABLE 14 
hs-CRP(mg/dl) 
No. of  Patients 
(n=70) 
Percentage 
(100%) 
< 0.3mg/dl 14 20.0 
> 0.3mg/dl 56 80.0 
 
In our study group hs- CRP was significantly elevated in 80% of the 
population.   
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ANALYSIS OF RESULTS 
TABLE 15 
 
SEX 
HSCRP  (mg/dl) 
Statistical 
inference 
Below 0.3 Above 0.3 Total 
(n=14) (100%) (n=56) (100%) (n=70) (100%) 
   Male 8 57.1% 46 82.1% 54 77.1% X
2=3.970 
Df=1 
.046<0.05 
Significant 
 
Female 
6 42.9% 10 17.9% 16 22.9% 
 
Using the chi-square test, the null hypothesis which states that there is no 
difference in hs-CRP levels between two sexes is disproved in our study. 
Here we have definitive evidence to prove that there is a statistically 
significant (p value <0.05) elevation of hs-CRP values of male COPD 
patients  when compared to female COPD patients. 
 
 
 
 
 
TABLE 16 
 
hs-CRP Mean S.D Statistical inference 
Non Smokers 
(n=15) 
7.3333 3.90671 
T=2.108 
.039<0.05 
Significant  Smokers (n=55) 5.2345 3.27890 
Df=68 
 
From the above table it is shown that smokers with COPD have 
significant raise in hs-CRP levels when compared to nonsmokers 
with COPD as proved by the unpaired T test which derived a P 
value of 0.039 which is statistically significant. 
 
 
 
 
 
 
 
TABLE 17 
hs-CRP Mean  S.D SS Df MS Statistical 
inference  
Between 
Groups 
  
291.062 3 97.021 
F=11.536 
.000<0.05 
Significant  
Stage 1 
(n=5) .8400 .67305    
Stage 2 
(n=6) 1.0667 .69186    
Stage 3 
(n=39) 6.5923 3.00888    
Stage 4 
(n=20) 6.5100 3.29959    
Within 
Groups 
  
555.091 66 8.410 
 
Using analysis of variance test (ANOVA) patients with stage 3 and 4 had 
significantly raised hs-CRP compared to other groups, as proven by the 
values mentioned.(p value < 0.000) 
 
 
 
 
 
 
 
 TABLE 18 
 
BMI Mean S.D Statistical inference 
Below 25 
(n=60) 
4.7517 2.83934 T=-7.188 
.000<0.05 
Significant  
31 & above 
(n=10) 
11.2800 .75982 
Df=68 
 
Using Unpaired T test it is proven that obese patients with COPD had 
significant elevation in hs- CRP levels when compared to non obese COPD 
patients. 
 
 
 
 
 
 
 
TABLE 19 
 
Using chi square test the tabulation above derives a  p value of 0.941 
(insignificant value).This shows that the hs-CRP levels is not related to the 
Age of the patient. 
 
 
 
 
AGE 
hs-CRP Statistical 
inference Below 0.3 Above 0.3 Total 
n=14 (100%) (n=56) (100%) (n=70) (100%) 
31 to 
40yrs 1 7.1% 5 8.9% 6 
 
8.6% 
 
X2=.781 
Df=4 
.941>0.05 
Not 
Significant  
41 to 
50yrs 4 28.6% 11 19.6% 15 
 
21.4% 
 
51 to 
60yrs 3 21.4% 17 30.4% 20 
 
28.6% 
 
61 to 
70yrs 5 35.7% 19 33.9% 24 
 
34.3 
 
 
 
 
DISCUSSION 
ANALYSIS OF hs-CRP LEVELS IN PATIENTS WITH ACUTE 
EXACERBATION OF COPD 
INFERENCE 1: 
Our study shows statistical evidence that hs-CRP levels are elevated in acute 
exacerbation of COPD. 
The above inference is supported by studies of  
Lisa tileman and Lena ginder at al., 72 
Sanja marevic et al., 67 
INFERENCE 2: 
In our study hs-CRP levels in male COPD patients are significantly elevated 
when compared to females. 
This above inference is supported by studies of 
SA alavi et al .,70 
Breyer et al., who also proposed that levels of hs-CRP are significantly 
elevated in male COPD patients.74 
 
 
 
 
INFERENCE 3: 
Levels of hs- CRP are increased significantly in smokers with COPD than in 
non smokers with COPD. 
Above statement is correlating with studies of  
Yannick et al.,69 
SA alavi et al.,70 
Lisa tileman et al., who said that levels of hs- CRP correlate with the pack 
years of smoking.72 
INFERENCE 4:  
Levels of hs-CRP are raised significantly in obese COPD patients compared 
to non obese individuals. 
According to PO Bridevaux et al., based on SAPALDIA study hs-CRP 
levels are significantly raised in obese COPD patients.71 
This fact is also supported by SA Alavi et al.,70 from Guilan university of 
Iran and Breyer et al. 74 
 
 
 
 
 
INFERENCE 5: 
In our study increase in hs- CRP levels are associated with the severity of 
the disease. 
This is supported by the studies of PO Bridevaux et al.,71 who concluded 
that hs- CRP levels are associated with fast FEV1 decline. 
INFERENCE 6: 
Our study shows no correlation between the disease duration and hs- CRP 
levels. 
This inference is supported by the results of Daiana stolz et al., 68 who 
concluded the same in a group of 100 patients for a follow up period of 
longer time >1yr. 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
1.The levels of  hs-CRP are elevated in acute exacerbation of COPD. 
2.The levels of hs-CRP are significantly elevated in male COPD patients. 
3.Smokers with COPD have statistically significant hs-CRP values than                  
nonsmokers with COPD. 
4.Levels of hs-CRP are significantly elevated in obese COPD patients. 
5.The hs-CRP values correlates with the severity of the disease. 
6.Levels of hs-CRP are independent of the duration of the disease. 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Serum high sensitivity CRP is a marker of systemic inflammation and 
functional disability in COPD patients. 
Increasing levels of hs-CRP may means the infectious state in human 
body and can guide the clinical treatment of  acute exacerbation of  COPD . 
The decrease in levels reflects the recovery period of Acute exacerbation of  
COPD. 
Serum hs-CRP may be used as a simple auxiliary marker  in staging 
and determining the prognosis of COPD for early intervention. 
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46 1412756 shanthi 31 F A A P A R A P P P P A A A A A A     P   19 20.5 6.3 
47 1420032 periyamma 60 F A A A P U P P A A P A A A P A A       P 14 33 10.8 
48 1404880 veeramal 60 F A P P A R A P P P P A A A P A A P       10 22.5 0.2 
49 1402493 kokila 53 F A A A A U A P P P P A A A A A A   P     9 21.5 2 
50 1400092 pattu 70 F A P P A R P P P P P P A P A A P     P   15 22 4.2 
51 1396574 kasthuri 45 F A A A P R A P P P P A A A P A A       P 18 19.5 8 
52 1398830 vazhambal 50 F A A P A U A P P P A A A A P A A       P 17 38 12.5 
53 1396563 vaduvambal 45 F A P A A R A P P A P A A A A A A     P   11 19.5 0.25 
54 1412687 saroja 60 F A A A A R P P P P P A A A P A A       P 13 20.5 6.9 
55 1369015 pushpavalli 67 F A A A A R A P P P P A A P A A A       P 28 21.5 6.2 
56 1371992 rajathi 58 F A P A P R A P P P A A A A P A A     P   3 22 6 
57 1377022 srisangam 50 M A A A A U P P P P A P A A A A P       P 18 32.5 11.6 
58 1379345 papathan 60 M 26 A A A R A P A P P A P A P P A       P 17 20.5 0.1 
59 1379345 noor mohamed 80 M 23 A P A U A P P P P A P A P P A       P 19 21.5 3.6 
60 1388547 saravanan 42 M 22.5 A P A R A P P P P A A P A A A     P   14 20 7.4 
61 1388555 rabuthul 40 M 21 A A A R P P P P P A A P P P A     P   13 23.5 8.5 
62 1321654 gunasekar 60 M 39.5 A P P R A P P P A A A A A A A     P   18 21.5 9.6 
63 1311789 rajan 57 M 37 A P A U A P P P P A A A A A A     P   17 33 12 
64 1313657 sasi 39 M 26 A P A U A P P P P A A A A A A     P   12 22 5.8 
65 1321589 shankar 49 M 28 A A A R A P P P P A P A A A A       P 19 19.5 5.8 
66 1402456 kumaran 58 M 22.5 A A A R P P P P P A A A P P A       P 18 20.6 6.2 
67 1412987 muthu 65 M A A P A R A P P P P A A A A A A     P   14 21.4 8.2 
68 1409321 selvaraj 71 M 31 A A P R A P A P A A A A A A A     P   13 20.6 5.6 
69 1420654 sathishkumar 35 M 23 A P A U A P P P A A A P A A A     P   12 21.7 6 
70 1402498 vijayan 50 M 21 A A A U A P P P P A P A P A A     P   12 23.5 3.2 
 
KEY TO MASTER CHART 
A – Cough  
B – Sputum production 
C – Dyspnea on exertion 
D – Wheeze 
E – Pedal edema 
F – Polycythemia  
G – Cyanosis   
H – Accessory muscles working 
I – Pursed lip breathing  
J – Jugular venous pressure  
hs-CRP- high sensitivity C reactive protein 
 BMI – Body Mass Index  
CRI  - Chronic Respiratory Infection 
P/Y – Pack years 
R/U –Rural /urban 
A- Absent 
P- Present 
 
